액섬 테라퓨틱스(AXSM)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $207.78 (-3.03%), 시가총액 $12.02B, 52주 최저~최고 $100.39 ~ $235.97.
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbr
액섬 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
액섬 테라퓨틱스의 현재 주가는 $207.78 (-3.03%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
액섬 테라퓨틱스의 시가총액은 약 $12.02B입니다.
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercia